Part Two: The MFN Drug Pricing Rule and the Rebate Rule: Where Do We Go From Here?

Rachel Alexander, Dorthula Powell-Woodson
Wiley Rein LLP
Contact
LinkedIn
Facebook
X
Send
Embed
In part two, Wiley Health Care Practice partners Dot Powell-Woodson and Rachel Alexander continue their discussion of the Most-Favored Nations (MFN) Rule and the Rebate Rule and look at the potential impacts of these Final Rules on managed care companies.
Embed
Copy
Send Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Wiley Rein LLP | Attorney Advertising

Written by:

Wiley Rein LLP
Wiley Rein LLP
Contact
more
less

Wiley Rein LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide